The two-evening programme on 27-28 January at The Ngee Ann Kongsi Auditorium at the SingHealth Duke-NUS campus convened clinicians, students, policymakers and partners to focus on the importance of outbreak preparedness and planetary health.

A team led by researchers at Chalmers University of Technology, Sweden, has succeeded in identifying biomarkers for Parkinson’s disease in its earliest stages, before extensive brain damage has occurred. The biological processes leave measurable traces in the blood, but only for a limited period. The discovery thus reveals a window of opportunity that could be crucial for future treatment, but also for early diagnosis via blood tests, which could begin to be tested in healthcare within five years.

The University of Osaka study shows that declining clinical tests lead to an underestimation of COVID-19 cases. By analyzing wastewater, researchers found viral loads remained high even as reported cases dropped. This highlights wastewater surveillance as a crucial, objective tool for accurately monitoring community-wide infection levels. The findings advocate for a multi-layered public health approach that is not solely reliant on testing data, ensuring a more realistic assessment of infection risks.

In a career defined by constant questioning, self-doubt can become an occupational hazard. Now, for the first time, a group of Cambridge scientists reveal the personal struggles they’ve faced – and continue to face – as they strive for success.

Scientists have developed a 3D, AI-based tool for viewing hearing cells. To understand hearing damage from noise and aging, and develop new treatments, scientists need detailed images of hair cells. The new VASCilia tool uses deep learning to accelerate sensory cell image processing and analysis.

Alliance Foundation Trials, LLC (AFT) today announced the publication of the pivotal phase III PATINA study (AFT-38) in the New England Journal of Medicine (NEJM), marking a major milestone for patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) advanced breast cancer (ABC). The study’s results demonstrate that the addition of the CDK4/6 inhibitor palbociclib to standard first-line maintenance therapy significantly prolongs progression-free survival (PFS) by more than 15 months compared with standard therapy alone.